Regeneron Pharmaceuticals Inc (REGN)
738.00
-6.50
(-0.87%)
USD |
NASDAQ |
Nov 22, 16:00
739.98
+1.98
(+0.27%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Financing (Quarterly): -634.00M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -634.00M |
| June 30, 2024 | -478.10M |
| March 31, 2024 | 47.10M |
| December 31, 2023 | -446.10M |
| September 30, 2023 | -407.30M |
| June 30, 2023 | -614.20M |
| March 31, 2023 | -322.50M |
| December 31, 2022 | -247.60M |
| September 30, 2022 | -725.00M |
| June 30, 2022 | -101.10M |
| March 31, 2022 | 64.70M |
| December 31, 2021 | -906.60M |
| September 30, 2021 | 385.40M |
| June 30, 2021 | -118.20M |
| March 31, 2021 | -366.40M |
| December 31, 2020 | -305.30M |
| September 30, 2020 | 612.00M |
| June 30, 2020 | -2.613B |
| March 31, 2020 | 335.60M |
| December 31, 2019 | -345.70M |
| September 30, 2019 | -11.00M |
| June 30, 2019 | -15.30M |
| March 31, 2019 | 119.90M |
| December 31, 2018 | -83.00M |
| September 30, 2018 | 3.70M |
| Date | Value |
|---|---|
| June 30, 2018 | -11.20M |
| March 31, 2018 | 13.40M |
| December 31, 2017 | -210.54M |
| September 30, 2017 | -8.196M |
| June 30, 2017 | 133.52M |
| March 31, 2017 | 60.81M |
| December 31, 2016 | -491.79M |
| September 30, 2016 | 28.68M |
| June 30, 2016 | -31.20M |
| March 31, 2016 | -206.19M |
| December 31, 2015 | -4.008M |
| September 30, 2015 | -345.65M |
| June 30, 2015 | -3.535M |
| March 31, 2015 | 90.40M |
| December 31, 2014 | -252.66M |
| September 30, 2014 | 5.166M |
| June 30, 2014 | -80.01M |
| March 31, 2014 | 108.95M |
| December 31, 2013 | 100.62M |
| September 30, 2013 | 3.533M |
| June 30, 2013 | -43.48M |
| March 31, 2013 | 11.52M |
| December 31, 2012 | -73.01M |
| September 30, 2012 | -1.809M |
| June 30, 2012 | -5.077M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.613B
Minimum
Jun 2020
612.00M
Maximum
Sep 2020
-359.30M
Average
-334.10M
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | -3.651B |
| Eli Lilly and Co | 211.30M |
| Pfizer Inc | -4.636B |
| Biogen Inc | -6.60M |
| AbbVie Inc | -3.072B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.291B |
| Cash from Investing (Quarterly) | -574.40M |
| Free Cash Flow | 3.319B |
| Free Cash Flow Per Share (Quarterly) | 9.030 |
| Free Cash Flow to Equity (Quarterly) | 1.049B |
| Free Cash Flow to Firm (Quarterly) | 1.049B |
| Free Cash Flow Yield | 3.91% |